Disclaimer

Information presented on this forum is designed for educational and informational purposes only. The information provided is not a substitute for professional, medical and health advice. Do not interpret or use this information to diagnose or treat a health problem or disease without consulting a professionally qualified health care provider. Please consult a relevant health care provider if You have any questions or concerns or if You wish to determine the information You are relying on is appropriate for Your medical condition/s.

Clinuvel does not endorse or attest to the validity or accuracy of any treatments or medications mentioned. Clinuvel makes no representations concerning the efficacy or suitability of any treatments, medications or products on this forum or website.

Clinuvel has made every effort to ensure the accuracy of information on this forum and welcomes Your feedback on any information. All feedback should be sent to the "Contact us" section. Clinuvel is not responsible or liable for any errors or omissions that may be found in the information provided or for the results obtained from the use of such information. Clinuvel encourages You to consult any other source and verify and confirm the information contained in any of the information, databases or pages accessible within or from this forum.

Further disclaimers apply to emails and Clinuvel announcements.

Clinuvel Blog Posts

“Basal cell carcinoma skin cancer is the most common form of skin cancer”. It’s a common claim and one which is undoubtedly true –...

Read More

Earlier today we announced that two health insurers in Switzerland had agreed to reimburse SCENESSE® (afamelanotide) for the rare disease...

Read More

In a letter published this week in the British Journal of Medicine three dermatologists have highlighted the potential risks posed by the...

Read More

Clinuvel Webcasts

Vitiligo is a skin disorder which causes the loss of pigment - melanin - in the skin. Though it affects around 45 million people worldwide,...

Watch now

On 31 January 2012 Swiss TV channel Telezueri aired a report on erythropoietic protoporphyria (EPP), a rare genetic disorder which causes ab...

Watch now

Following Clinuvel's landmark filing of a marketing authorisation application for the drug SCENESSE® (afamelanotide) with the European Medic...

Watch now

Clinuvel Spotlight

The technology behind Clinuvel’s lead drug, SCENESSE® (afamelanotide), has been in research and development since the 1980s when a small team of scientists set out to investigate methods of preventing skin cancer in humans. Clinuvel licensed this technology and has spent over A$20million optimising the chemistry of afamelanotide (the active ingredient in SCENESSE®) an...

Read more